C12N 2710/10021
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2710/10021 (Viruses as such) appears on 54 US grants and 93 published applications in this corpus.
Search patents in C12N- Granted patents
- 54
- Published applications
- 93
- Assignees
- 57
- Inventors
- 145
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 2 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 4 |
| 2014 | 2 | 4 |
| 2015 | 3 | 10 |
| 2016 | 6 | 11 |
| 2017 | 3 | 3 |
| 2018 | 4 | 7 |
| 2019 | 3 | 8 |
| 2020 | 5 | 8 |
| 2021 | 5 | 8 |
| 2022 | 6 | 4 |
| 2023 | 3 | 5 |
| 2024 | 6 | 4 |
| 2025 | 4 | 8 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic adenovirus compositions31 Mar 2026US 12,589,128 B2The Salk Institute for Biological Studies
- Dosing regime and formulations for type B adenoviruses8 Jul 2025US 12,350,302 B2Akamis Bio Limited
- Targeted neoepitope vectors and methods therefor27 May 2025US 12,311,018 B2NantCell, Inc.
- Oncolytic virus expressing PD-1 binding protein and application of oncolytic virus25 Mar 2025US 12,258,408 B2Shanghai Yuansong Biotechnology Co. Ltd.
- Tumor-selective E1a and E1b mutants14 Jan 2025US 12,195,766 B2The Regents of the University of California
- Dosing regime and formulations for type b adenoviruses30 Jul 2026US 2026/0216263 A1Akamis Bio Limited
- Oncolytic adenoviral vector and methods of use16 Apr 2026US 2026/0102445 A1Unleash Immuno Oncolytics, Inc.
- Tumor-selective e1a and e1b mutants23 Oct 2025US 2025/0327037 A1The Regents of the University of California
- Anti-gucy2c vaccines and vaccination9 Oct 2025US 2025/0312429 A1Thomas Jefferson University
- Methods of treating solid or lymphatic tumors by combination therapy2 Oct 2025US 2025/0302897 A1Cg Oncology, Inc.
Most cited
By later US patents
- Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof48US 8,834,863 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric adenoviruses for use in cancer treatment33US 7,510,868 B22009
- Simian adenovirus and hybrid adenoviral vectors21US 9,714,435 B2Oxford University Innovation Limited · 2017
- Recombinant serotype 5 (Ad5) adenoviral vectors16US 9,410,129 B2Targovax Oy · 2016
- Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof12US 10,149,873 B2The Trustees of the University of Pennsylvania · 2018